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scleritis is achieved through observation of sun set glow 
fundus and neurologic or dermatologic signs not seen in 
posterior scleritis. Posterior scleritis is also usually unilat-
eral, and T-sign is a unique characteristic of this disease. 
Recently, there have been some reports, especially in Ja-
pan, of posterior scleritis appearing concurrently with 
VKH disease in patients; Kouda et al. [4] reported that 
posterior scleritis was an early manifestation of VKH.
In our case, neurologic symptoms such as headache and 
tinnitus appeared as clinical features of VKH, while 
T-sign and lid swelling were signs of posterior scleritis. 
Anterior chamber reaction and serous retinal detachment 
were also observed in both VKH and posterior scleritis. 
Thus, we conclude that our case involved unilateral VKH 
disease with posterior scleritis.
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Intravitreal Bevacizumab for the 
Treatment of Optic Disc Edema in a 
Patient with POEMS Syndrome
Dear Editor,
Polyneuropathy, organomegaly, endocrinopathy, mono-
clonal gammopathy, and skin changes (POEMS) syndrome 
is a rare multisystem disorder of obscure etiology that is 
associated with plasma cell dyscrasia [1]. Optic disc edema 
(ODE) has been reported to be a common ocular manifes-
tation of POEMS syndrome [2]. Vascular endothelial 
growth factor (VEGF) has been regarded to have an im-
portant role in the pathophysiology of POEMS syndrome. 
We present a case of a young female patient presenting 
with bilateral optic nerve head edema after being diag-
nosed with POEMS syndrome, who was successfully treat-
ed with repeated intravitreal bevacizumab injections. The 
study protocol was approved by the Institutional Review 
Board of Yonsei University Severance Hospital and fol-
lowed the tenets of the Declaration of Helsinki.
A 34-year-old female patient presented with progressive 
narrowing of her visual field (VF). She had been diagnosed 
with POEMS syndrome 3 months previously at the depart-
ment of hemato-oncology and had received palliative ra-
diotherapy of 5,000 cGy to her right iliac crest, in which a 
plasmacytoma was located. She was also prescribed thalid-
omide 100 mg/day orally. According to her medical re-
cords, she had bilateral ODE at the time of diagnosis. At 
that time, lumbar puncture had revealed a slightly increased 
intracranial pressure of 16.18 mmHg. Her best-corrected 
visual acuity and intraocular pressure were 20 / 25 and 18 
mmHg, respectively. There were no abnormal findings in 
either eye, with the exception of severe bilateral ODE. 
Automated perimetry showed bilateral enlarged blind 
spots and VF constriction. A f luorescein angiogram re-
vealed early, well delineated hyperfluorescence in both op-
tic discs, compatible with ODE (Fig. 1A-1H). Indocyanine 
green angiography revealed no abnormalities of choroidal 
perfusion.  
Although her central vision was largely unaffected, the 
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Fig. 1. Fundus photographs, fluorescein angiograms, and Humphrey automated perimetry (HAP) before and 3 months after the last in-
travitral bevacizumab Injection. (A,B) Bilateral fundus photographs showing optic nerve head edema (ODE). The disc is congested and 
hyperemic with elevation of the retinal surface. Signs of secondary gliosis due to long term ODE are evident (fundus camera; Canon, 
Tokyo, Japan) (A, right eye; B, left eye). (C,D) Bilateral fluorescein angiograms and indocyanine green angiograms showing early irreg-
ular hyperfluorescence emanating from the disc and spreading to the proximal vascular arcades. Long standing fibrotic change, probably 
due to secondary gliosis, is also present. Indocyanine green angiograms A shows mild blocked-fluorescence at the disc with no abnormal 
choroidal perfusion (0:58.23, 30 degrees; Heidelberg Retinal Angiogram 2, Heidelberg Engineering, Heidelberg, Germany) (C, right eye; 
D, left eye). (E,F) Bilateral fundus photographs 3 months after the last intravitreal bevacizumab injections. Resolution of the prior ODE is 
evident (E, right eye; F, left eye). (G,H) Bilateral fluorescein angiograms of the same patient 3 months after the last injection of intravitre-
al bevacizumab. The disc is only mildly stained in the late phase, with no evidence of active leakage (20:04.09) (G, right eye; H, left eye). 
(I,J) Pre-injection HAP showing enlarged inferior blind spots and superior arcuate visual field defects developing in the right (I) and left (J) 
eyes, respectively. (K,L) HAP three months after the last intravitreal bevacizumab injection showing resolution of the previous scotomata 
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patient complained of progressively enlarging VF defects, 
which was confirmed by automated perimetry. The wors-
ening VF defects coupled with the presence of ODE fol-
lowing the completion of radiotherapy warranted further 
intervention. Bilateral intravitreal bevacizumab injections 
were performed after informed consent had been obtained. 
Quantification of the intravitreal VEGF at the time of in-
jection was within the established normal range (<30 pg/
mL); however, the systemic VEGF level was elevated at 
166.0 pg/mL (normal, 0 to 38.3 pg/mL).
One week after the intravitreal injection of bevacizumab, 
repeat fluorescein angiogram and fundus photography re-
vealed bilateral regression of the ODE accompanied by im-
provement in the VF. Approximately 50 days later, the pa-
tient complained of recurring VF defects, and increasing 
ODE was observed in both eyes. Repeat bilateral injections 
were administered with improvement in both the symp-
toms and ODE (Fig. 1I-1L). At follow-up 11 months after 
the injections, the patient had 20 / 20 vision with complete 
regression of the ODE, likely due to systemic improve-
ment.
The presence of ODE in POEMS syndrome has been 
well documented [2]. However, its etiology remains a mat-
ter of controversy. Increased systemic VEGF [3], increased 
intracranial pressure [4], nerve infiltration [5], and vascular 
hyperpermeability [4] have been suggested as possible 
causes.
The patient presented here showed an initial improve-
ment in symptomatic ODE after intravitreal bevacizumab 
injection; however, the ODE redeveloped approximately 50 
days later. This timeline coincides with the known dura-
tion of anti-VEGF antibody. The successful management 
of ODE with anti-VEGF therapy before systemic improve-
ment seems to imply that VEGF is an important compo-
nent in the pathophysiology of ODE in POEMS syndrome. 
The lack of increase in VEGF titer from vitreous samples 
in our case coincides with data from previous report [3]. 
This suggests that ocular manifestations, such as ODE, are 
related to elevated level of systemic VEGF rather than in-
traocular VEGF. Systemic VEGF might alter optic nerve 
head vascular permeability via the choroidal blood f low, 
which is relatively free to communicate with the systemic 
circulation. 
We report a case of POEMS syndrome that was treated 
with intravitreal bevacizumab injection. Our findings sug-
gest that the cause of ODE in POEMS syndrome might be 
associated with VEGF. A relationship between the cause 
of ODE in POEMS syndrome and systemic VEGF should 
be further investigated.
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